Maplight Therapeutics (NASDAQ:MPLT) Research Coverage Started at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics (NASDAQ:MPLT) in a report released on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $35.00 price target on the stock.

MPLT has been the subject of several other reports. Stifel Nicolaus began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective for the company. Leerink Partners started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 target price on the stock. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.80.

Maplight Therapeutics Stock Performance

NASDAQ MPLT opened at $17.56 on Thursday. The firm has a 50 day moving average price of $17.88. The stock has a market capitalization of $796.70 million and a P/E ratio of -0.47. Maplight Therapeutics has a 1-year low of $12.24 and a 1-year high of $21.55.

Insider Activity

In other news, Director George Pavlov purchased 10,658 shares of the stock in a transaction dated Wednesday, February 18th. The shares were purchased at an average price of $17.48 per share, with a total value of $186,301.84. Following the transaction, the director owned 10,658 shares in the company, valued at $186,301.84. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy John Garnett bought 14,124 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was purchased at an average price of $17.89 per share, for a total transaction of $252,678.36. Following the completion of the acquisition, the director directly owned 14,124 shares in the company, valued at $252,678.36. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Strs Ohio acquired a new stake in shares of Maplight Therapeutics during the fourth quarter valued at about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $93,000. MetLife Investment Management LLC purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.